{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:14:38Z","timestamp":1710342878361},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[1999,12,1]],"date-time":"1999-12-01T00:00:00Z","timestamp":944006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>One of the aims of the treatment of Paget's disease with bisphosphonates should be the normalization of the activity of the disease with the shortest possible exposure to the drug. Olpadronate (OPD) is a new bisphosphonate characterized by the dimethylation of the amino group, its potency is near to alendronate, and more soluble in the digestive media than other aminobisphosphonates. We treated 46 patients (28 men and 18 women, mean age 70 years) with active Paget's disease with oral OPD, 200 mg\/day for 12 \u00b1 2 days, except 2 patients who received 400 mg\/day. Eight patients had never been treated before, and 38 had previously received antiosteolytic drugs. The period without treatment prior to OPD was (X \u00b1 1 SD) 14 \u00b1 12 months. Baseline bone alkaline phosphatase (BALP) (levels fell from (X \u00b1 1 SD) 54.0 \u00b1 62.7 IU\/ml (range 22\u2013396) to a lowest mean value of 16.2 \u00b1 6.4 IU\/ml (range 8\u201345) (normal range 5\u201321 IU\/ml). Forty patients normalized BALP values, in most of the cases within the first 3 months after OPD treatment. Two patients showed partial response (&amp;gt; 50% decrease from baseline), three patients presented poor response (&amp;lt; 50% decrease from baseline), and one patient did not respond at all. Two patients complained of gastric discomfort, and one patient had diarrhea, which disappeared after discontinuation of the drug. Follow-up was carried out on 36 patients; 22 patients are still in remission, with an average length of 9.0 \u00b1 2.6 months. Fourteen patients experienced relapse after 9 \u00b1 2 months remission. In conclusion, a 12-day treatment with 200 mg\/day of OPD proved to be a very effective and well tolerated therapy of Paget's disease and induced biochemical remissions in the vast majority of patients, even in those with very active disease.<\/jats:p>","DOI":"10.1359\/jbmr.1999.14.12.2042","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T01:19:48Z","timestamp":1146100788000},"page":"2042-2047","source":"Crossref","is-referenced-by-count":8,"title":["Short-Term Therapy with Oral Olpadronate in Active Paget's Disease of Bone"],"prefix":"10.1093","volume":"14","author":[{"given":"Diana C.","family":"Gonz\u00e1lez","sequence":"first","affiliation":[{"name":"Centro de Osteopat\u00edas M\u00e9dicas, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Mautalen","sequence":"additional","affiliation":[{"name":"Centro de Osteopat\u00edas M\u00e9dicas, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024020713334854900_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1359\/jbmr.1998.13.7.1061","article-title":"Clinical Review: Paget's disease of bone","volume":"13","author":"Siris","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024020713334854900_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0950-351X(97)80553-8","article-title":"Paget's disease of bone: Clinical, pathogenetic and therapeutic aspects","volume":"11","author":"Papapoulos","year":"1997","journal-title":"Bailliere's Clin Endocrinol Metab"},{"key":"2024020713334854900_bib3","first-page":"29","article-title":"Enhancement of the inhibitory action of APD on the transformation of osteoclasts precursors into resorting cells after dimethylation of the amino group","volume":"2","author":"Boonekamp","year":"1987","journal-title":"Bone Miner"},{"key":"2024020713334854900_bib4","first-page":"103","article-title":"Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile","volume":"20","author":"Vega","year":"1994","journal-title":"Drugs Exp Clin Res"},{"issue":"Suppl 1","key":"2024020713334854900_bib5","first-page":"25","article-title":"Tratamiento de la enfermedad de Paget con olpadronato: Su eficacia terap\u00e9utica en respondedores parciales al pamidronato oral","volume":"57","author":"Gonz\u00e1lez","year":"1997","journal-title":"Medicina (Buenos Aires)"},{"key":"2024020713334854900_bib6","first-page":"45","volume-title":"Bisphosphonates in bone disease. From the Laboratory to the Patient","author":"Fleisch","year":"1997","edition":"3rd Ed."},{"key":"2024020713334854900_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jbmr.5650080208","article-title":"Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate","volume":"8","author":"Schweitzer","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020713334854900_bib8","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1093\/clinchem\/32.10.1960","article-title":"Quantification of bone alkaline phosphatase in serum by precipitation with wheat germ lectin a simplified method and its clinical plausibility","volume":"32","author":"Behr","year":"1986","journal-title":"Clin Chem"},{"key":"2024020713334854900_bib9","first-page":"864","article-title":"Application of an enzyme immunoassay for a new marker of bone resorption (crosslaps): Follow up on hormone replacement therapy and osteoporotic risk fracture","volume":"80","author":"Bonde","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713334854900_bib10","first-page":"3993","article-title":"Predition of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption","volume":"81","author":"Papapoulos","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713334854900_bib11","first-page":"217","volume-title":"Pathophysiology and Treatment of Paget's Disease of Bone","author":"Kanis","year":"1991"},{"key":"2024020713334854900_bib12","first-page":"961","article-title":"Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone","volume":"81","author":"Siris","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713334854900_bib13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/8756-3282(85)90219-4","article-title":"Efficacy of the bisphosphonate APD in the control of Paget's bone disease","volume":"6","author":"Mautalen","year":"1985","journal-title":"Bone"},{"key":"2024020713334854900_bib14","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/jbmr.5650081209","article-title":"Determinants of remission of Paget's disease of bone","volume":"8","author":"Patel","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024020713334854900_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF01320908","article-title":"Pamidronate is effective for Paget's disease of bone refractory to conventional therapy","volume":"53","author":"Wimalawansa","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"2024020713334854900_bib16","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.295.6609.1301","article-title":"Paget's disease of bone early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD)","volume":"295","author":"Harinck","year":"1987","journal-title":"Br Med J"},{"key":"2024020713334854900_bib17","first-page":"1906","article-title":"Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease","volume":"83","author":"Singer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020713334854900_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF02509539","article-title":"High-dose pamidronate in the management of resistant Paget's disease","volume":"58","author":"Cundy","year":"1996","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 3","key":"2024020713334854900_bib19","first-page":"513","article-title":"Clinical pharmacology of alendronate sodium","volume":"3","author":"Gertz","year":"1993","journal-title":"Osteoporos Int"},{"key":"2024020713334854900_bib20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00003086-198606000-00028","article-title":"Spontaneous fractures of uninvolved bones in patients with Paget's disease during unduly prolonged treatment with disodium etidronate (EHDP)","volume":"207","author":"Mautalen","year":"1986","journal-title":"Clin Orthop"},{"key":"2024020713334854900_bib21","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/0140-6736(93)92935-M","article-title":"Mineralisation defects with pamidronate therapy for Paget's disease","volume":"342","author":"Adamson","year":"1993","journal-title":"Lancet"},{"key":"2024020713334854900_bib22","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/clinchem\/41.11.1592","article-title":"Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease","volume":"41","author":"Blumsohn","year":"1995","journal-title":"Clin Chem"},{"key":"2024020713334854900_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s002239900093","article-title":"Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate","volume":"59","author":"De la Piedra","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"2024020713334854900_bib24","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/art.1780380620","article-title":"Comparative prospective double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone","volume":"38","author":"Roux","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2024020713334854900_bib25","doi-asserted-by":"crossref","first-page":"493S","DOI":"10.1016\/8756-3282(95)00282-1","article-title":"Tiludronate therapy for Paget's disease of bone","volume":"17","author":"McClung","year":"1995","journal-title":"Bone"},{"key":"2024020713334854900_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S8756-3282(96)00364-X","article-title":"Alendronate in the treatment of Paget's disease of bone","volume":"20","author":"Khan","year":"1997","journal-title":"Bone"},{"key":"2024020713334854900_bib27","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/8756-3282(94)90818-4","article-title":"Effects of two oral doses of alendronate in the treatment of Paget's disease of bone","volume":"15","author":"Adami","year":"1994","journal-title":"Bone"},{"key":"2024020713334854900_bib28","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","article-title":"Risedronate in the treatment of Paget's disease of bone: An open label, multicenter study","volume":"13","author":"Siris","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024020713334854900_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S8756-3282(97)00222-6","article-title":"Paget's disease of bone: Reduction of disease activity with oral risedronate","volume":"22","author":"Hosking","year":"1998","journal-title":"Bone"},{"issue":"Suppl","key":"2024020713334854900_bib30","doi-asserted-by":"crossref","first-page":"69S","DOI":"10.1016\/S8756-3282(99)00069-1","article-title":"Prediction and assessment of the response of Paget's disease to bisphosphonate treatment","volume":"24","author":"Hosking","year":"1999","journal-title":"Bone"},{"key":"2024020713334854900_bib31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S8756-3282(96)00368-7","article-title":"Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone","volume":"20","author":"Devogelaer","year":"1997","journal-title":"Bone"},{"key":"2024020713334854900_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF01351831","article-title":"Pharmacokinetic evaluation of pamidronate after oral administration: A study on dose proportionality, absolute bioavailability, and effect of repeated administration","volume":"53","author":"Hydlstrup","year":"1993","journal-title":"Calcif Tissue Int"},{"key":"2024020713334854900_bib33","first-page":"1123","article-title":"Olpadronic acid sodium salt IG-8801: Treatment for Paget's bone disease. Treatment for osteoporosis","volume":"20","author":"Roldan","year":"1995","journal-title":"Drugs Future"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.1999.14.12.2042","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/14\/12\/2042\/56599169\/5650141208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/14\/12\/2042\/56599169\/5650141208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:57:37Z","timestamp":1710341857000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/14\/12\/2042-2047\/7514730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,12,1]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[1999,12,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.1999.14.12.2042","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1999,12,1]]},"published":{"date-parts":[[1999,12,1]]}}}